28 results about "B-Cell Maturation Antigen" patented technology

The invention discloses a neutralizing nucleic acid aptamer for targeted inhibition of a B cell activating factor and application of the neutralizing nucleic acid aptamer in treatment of systemic lupus erythematosus. The neutralizing aptamer disclosed by the invention can be used for efficiently inhibiting the combination of BAFF and specific receptors on a B cell membrane, including a BAFF receptor (BAFF-R), a human calcium regulatory cyclophilin ligand interaction molecule (TACI) and a B cell maturation antigen (BCMA), so that the proportion of plasma cells, plasma mother cells and hair growth center B cells is reduced, and finally, the generation and secretion of autoantibodies are reduced; the compound has a targeted therapeutic effect on systemic lupus erythematosus. Compared with an existing biological agent for neutralizing BAFF, the neutralizing nucleic acid aptamer has the advantages of being high in specificity, high in affinity, easy to synthesize, low in immunogenicity, low in cost, capable of being designed and programmed and the like, is a potential novel nucleic acid preparation for SLE targeted therapy, and has a good clinical transformation application prospect.

The disclosure concerns a method of treating cancer, especially, such as multiple myeloma, involving the combination of an anti-BCMA (B cell maturation antigen) antibody, Belantamab mafodotin -GSK2857916- and a gamma-secretase inhibitor, e.g., nirogacestat -PF03084014-. The disclosure also relates to dosages, duration of treatment and time lapses between administration of the anti-BCMA antibody and the gamma-secretase inhibitor.

The present disclosure belongs to the fields of biotechnology and biological medicine, and specifically relates to an antibody targeting a B cell maturation antigen (BCMA) and related products thereof and medical applications. Specifically, the antibody contains a variable light chain and a variable heavy chain. The variable light chain contains a light chain complementarity-determining region (CDR) 1, a light chain CDR2, and a light chain CDR3. The light chain CDR1 has a sequence as shown in SEQ ID NO. 1, the light chain CDR2 has an amino acid sequence as shown in SEQ ID NO. 2, and the light chain CDR3 is as shown in SEQ ID NO. 3 or SEQ ID NO. 4.

This provides a multispecific antibody that binds to BCMA. [Solution] A multispecific human heavy chain antibody (e.g., UniAb) that binds to B cell maturation antigen (BCMA). TM Disclosed are methods for producing such antibodies, compositions comprising pharmaceutical compositions containing such antibodies, and their use for treating disorders characterized by BCMA expression. In one embodiment, a multispecific antibody that binds to BCMA is provided, comprising a first binding unit comprising a variable region comprising a CDR3 sequence having at least 85% sequence identity with a specific sequence.

The present disclosure relates to compositions and methods for treating diseases using chimeric antigen recipient cells and / or antigen binding domains that target BCMA.

This invention relates to GPRC5D and BCMA-specific chimeric antigen receptors (CARs), specifically providing CARs containing an extracellular antigen-binding domain that binds to a G protein-coupled receptor class C5 group D member (GPRC5D) and B cell maturation antigen (BCMA). The invention also relates to genetically engineered cells expressing such CARs and their use in adoptive cell therapy.

Antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor are disclosed. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

Compositions and methods described herein relate to chimeric antigen receptors (CARs) targeting B cell maturation antigen (BCMA) and uses thereof in therapy. Engineered T cells comprising an anti-BCMA CAR are also provided. The engineered cells may comprise a genetic modification in one or more of the HLA-A, HLA-B, TRAC, CIITA, or TGFBR2 genes.

The application discloses a neutralizing nucleic acid aptamer capable of specifically combining with human APRIL and application thereof in inhibiting antibody secretion. The neutralizing nucleic acid aptamer of the application can efficiently neutralize extracellular APRIL molecules in vitro and in vivo, thereby blocking the combination of the molecules with a human calcium-binding cyclophilin ligand-interacting molecule (TACI) and a B cell maturation antigen (BCMA) on a B cell membrane, and finally inhibiting the generation and secretion of antibodies. Compared with the existing biological preparation atacicept for targeting and neutralizing APRIL, the APRIL neutralizing nucleic acid aptamer involved in the application has the advantages of high specificity, high affinity, low immunogenicity and low cost, is a novel nucleic acid drug preparation for inhibiting antibody secretion, and has a great clinical application prospect.

The present disclosure is based at least in part on the discovery of novel BCMA antibodies or antigen-binding fragments thereof, and generally, genetically modified cells (e.g., iNKT cells, CAR T cells, etc.) expressing chimeric antigen receptors comprising anti-BCMA antibodies or antigen-binding fragments thereof exhibit improved properties, including increased binding to BCMA, killing of BCMA-expressing cancer cells in vitro and in vivo, and enhanced persistence in treated subjects.

To provide compositions and methods that can be used in methods to treat multiple myeloma.SOLUTION: The invention provides an isolated or purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.SELECTED DRAWING: None

The present disclosure is based, at least in part, on the discovery of novel BCMA antibodies or antigen-binding fragments thereof, and genetically modified cells (e.g., iNKT cells, CAR T cells, etc.) expressing chimeric antigen receptors comprising anti-BCMA antibodies or antigen-binding fragments thereof exhibit improved properties, including increased binding to BCMA, in vitro and in vivo killing of cancer cells expressing BCMA; and enhanced persistence in a subject receiving therapy.

There is provided a method of treating an autoimmune disease comprising administering to a patient a cell composition made by transducing cells with a mixture of vectors, the mixture comprising: (i) a first vector which expresses a first chimeric antigen receptor (CAR) which binds CD19; and (ii) a second vector which expresses a second CAR which binds B cell maturation antigen (BCMA). There is also provided a method for selectively deleting anti-BCMA CAR-expressing cells and a method for restoring the plasma cell compartment in a patient who has received such a treatment.

Compositions and methods of treatment that can be used in the treatment of multiple myeloma are provided. The present invention provides an isolated or purified nucleic acid sequence encoding a chimeric antigen receptor (CAR), the CAR comprising an antigen recognition portion and a T cell activation portion, the antigen recognition portion being directed against B cell maturation antigen (BCMA), and a host cell, such as a T cell or a natural killer (NK) cell, that expresses the CAR.

The present disclosure provides compositions and methods for inhibiting or preventing an immune response to an immunogen (e.g., an immunogenic delivery vehicle) in a subject in need thereof, comprising administering to the subject an effective amount of a plasma cell depleting agent, e.g., an antigen-binding molecule that binds to B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) (e.g., an anti-BCMAxCD3 bispecific antibody, or a functional fragment thereof) or a B cell depleting agent, e.g., an antigen-binding molecule that binds to CD20 and CD3 (e.g., an anti-CD20xCD3 bispecific antibody, or a functional fragment thereof), either alone or in combination with one another, and / or in combination with an immunoglobulin depleting agent such as a neonatal fragment crystallizable (Fc) receptor (FcRn) blocker (e.g., efgartigimod).

The present invention concerns antigen binding proteins and fragments thereof which specifically bind B Cell Maturation Antigen (BCMA), particularly human BCMA (hBCMA) and which inhibit the binding of BAFF and APRIL to the BCMA receptor. Further disclosed are pharmaceutical compositions, screening and medical treatment methods.

This disclosure provides a method for treating a subject with cancer or light chain amyloidosis, the method comprising administering to the subject a combination therapy containing an effective amount of nirostat dihydrobromide form A and B cell maturation antigen (BCMA) targeted therapy and providing the use of the combination therapy.

The present invention relates to novel humanized antibodies that bind to the B cell maturation antigen (BCMA), and to immunostimulatory antigen binding molecules comprising these BCMA antibodies, in particular to antigen binding molecules comprising a 4-1BBL trimer that target BCMA; processes for their production; and their use in the treatment of cancer.

Genetically engineered immune cells (e.g., T cells or NK cells) that express anti-BCMA, anti-TACI, or anti-BCMA / anti-TACI chimeric antigen receptors and their use in cancer treatment. In some embodiments, the genetically engineered immune cells may be armed CAR-T or CAR-NK cells that further express arming polypeptides to enhance the characteristics of the CAR-T or CAR-NK cells.

Provided are CAR-T cells targeting BCMA and CD19. Specifically, provided is a parallel expression structure for chimeric antigen receptors (CARs) for B cell maturation antigen (BCMA) and a CD19 antigen molecules, and optimizes a CD28 costimulatory domain motif. Further provided is a use of the chimeric antigen receptors for adoptive T cell therapy for B cell-related conditions.

The present invention provides a chimeric antigen receptor (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.

This invention provides antibodies that recognize the B Cell Maturation Antigen (BCMA) and that bind naïve B cells, plasma cells, and / or memory B cells. The invention further provides methods for depleting naïve B cells, plasma cells, and memory B cells, and for treating B cell-related disorders, including lymphomas and autoimmune diseases.

The present disclosure provides compositions and methods for inhibiting or preventing an immune response to an immunogen (e.g., an immunogenic delivery vehicle) in a subject in need thereof, comprising administering to the subject an effective amount of a plasma cell depleting agent, e.g., an antigen-binding molecule that binds to B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) (e.g., an anti-BCMAxCD3 bispecific antibody, or a functional fragment thereof) or a B cell depleting agent, e.g., an antigen-binding molecule that binds to CD20 and CD3 (e.g., an anti-CD20xCD3 bispecific antibody, or a functional fragment thereof), either alone or in combination with one another, and / or in combination with an immunoglobulin depleting agent such as a neonatal fragment crystallizable (Fc) receptor (FcRn) blocker (e.g., efgartigimod).

This invention relates to CAR-T cells targeting BCMA and CD19. Specifically, the invention provides a structure for the parallel expression of a chimeric antigen receptor (CAR) that simultaneously targets B cell maturation antigen (BCMA) and CD19 antigen molecules, and optimizes the motif of the co-stimulatory domain CD28. The invention further provides applications of the chimeric antigen receptor for adoptive T cell therapy for B cell-related conditions.

The present invention provides therapeutics for the treatment of Multiple myeloma. In particular, the present invention provides chimeric antigen receptor (CAR) T-cells that can target the B cell maturation antigen.

This document provides chimeric antigen receptors (CARs) and CAR-NK cells targeting BCMA and GPRC5D, and their use in the treatment of multiple myeloma (MM). Specifically, this disclosure relates to bispecific CARs, the corresponding encoding polynucleotides of the CARs, and vectors containing the polynucleotides, said CARs comprising: (a) a B cell maturation antigen (BCMA) targeting domain; and (b) a G protein-coupled receptor C family 5 member D (GPRC5D) targeting domain, preferably armed with IL-15, etc. Furthermore, this document also provides CAR-NK cells modified with one or more CARs, and the use of CARs and CAR-NK cells in the treatment of MM.

This disclosure relates to compositions and methods for treating disease using chimeric antigen receptor cells and / or antigen binding domains targeting BCMA.

The invention discloses a neutralizing nucleic acid aptamer capable of being specifically combined with human APRIL and application of the neutralizing nucleic acid aptamer in inhibition of antibody secretion. The neutralizing aptamer disclosed by the invention can efficiently neutralize extracellular APRIL molecules in vivo and in vitro so as to block the combination of the APRIL molecules with human calcium regulatory cyclophilin ligand interaction molecules (TACI) and B cell maturation antigen (BCMA) on a B cell membrane and finally inhibit the generation and secretion of an antibody. Compared with the existing biological agent tetrobercept for targeted neutralization of APRIL, the APRIL neutralization aptamer provided by the invention has the advantages of strong specificity, high affinity, low immunogenicity, low cost and the like, is a novel nucleic acid medicinal preparation for inhibiting antibody secretion, and has a relatively great clinical application prospect.